Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats.
Rongqian Wu, Weifeng Dong, Mian Zhou, Fangming Zhang, Corrado P Marini, Thanjavur S Ravikumar, Ping Wang
Index: Am. J. Respir. Crit. Care Med. 176(8) , 805-13, (2007)
Full Text: HTML
Abstract
Our study has shown that plasma levels of ghrelin, a stomach-derived peptide, are significantly reduced in sepsis, and that ghrelin administration improves organ blood flow via a nuclear factor (NF)-kappaB-dependent pathway. However, it remains unknown whether ghrelin has any protective effects on severe sepsis-induced acute lung injury (ALI) and, if so, whether inhibition of NF-kappaB plays any role in it.To test the hypothesis that ghrelin reduces severe sepsis-induced ALI and mortality through inhibition of NF-kappaB.Sepsis was induced in rats by cecal ligation and puncture (CLP). Five hours after CLP, a bolus intravenous injection of 2 nmol of ghrelin was followed by continuous infusion of 12 nmol of ghrelin via a minipump for 15 hours. Samples were harvested 20 hours post-CLP (i.e., severe sepsis). Pulmonary levels of ghrelin and proinflammatory cytokines were measured by ELISA. NF-kappaB p65 and IkappaBalpha expression and NF-kappaB activity were measured by Western blot analysis and ELISA, respectively. Pulmonary blood flow was measured with radioactive microspheres. In additional animals, the necrotic cecum was excised 20 hours post-CLP and 10-day survival was recorded.Pulmonary levels of ghrelin decreased significantly 20 hours post-CLP. Ghrelin administration restored pulmonary levels of ghrelin, reduced lung injury, increased pulmonary blood flow, down-regulated proinflammatory cytokines, inhibited NF-kappaB activation, and improved survival in sepsis. Administration of a specific ghrelin receptor antagonist worsened the survival rate after CLP and cecal excision.Ghrelin can be developed as a novel treatment for severe sepsis-induced ALI. The protective effect of ghrelin is mediated through inhibition of NF-kappaB.
Related Compounds
Related Articles:
2013-03-08
[PLoS ONE 9(7) , e103118, (2014)]
2014-07-01
[Endocrinology 155(7) , 2658-66, (2014)]
2007-01-01
[Int. J. Biochem. Cell Biol. 39(4) , 752-64, (2007)]
1993-01-01
[Peptides 14 , 109-115, (1993)]
1994-06-01
[J. Pharm. Biomed. Anal. 12 , 811-819, (1994)]